ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone353-1291-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.60 billion
Profitability
Miscellaneous
Employees13,670
Next Earnings Date10/23/2019 (Confirmed)
OptionableOptionable
Icon (NASDAQ:ICLR) Frequently Asked Questions
What is Icon's stock symbol?
Icon trades on the NASDAQ under the ticker symbol "ICLR."
How were Icon's earnings last quarter?
Icon Plc (NASDAQ:ICLR) announced its quarterly earnings data on Wednesday, October, 24th. The medical research company reported $1.54 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.54. The medical research company earned $655.02 million during the quarter, compared to analysts' expectations of $654.66 million. Icon had a net margin of 13.05% and a return on equity of 25.02%. View Icon's Earnings History.
When is Icon's next earnings date?
What price target have analysts set for ICLR?
8 analysts have issued 1-year target prices for Icon's stock. Their forecasts range from $154.00 to $170.00. On average, they anticipate Icon's stock price to reach $162.67 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View Analyst Price Targets for Icon.
What is the consensus analysts' recommendation for Icon?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.
Has Icon been receiving favorable news coverage?
Press coverage about ICLR stock has been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Icon earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Icon.
Are investors shorting Icon?
Icon saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 528,500 shares, an increase of 17.4% from the August 30th total of 450,300 shares. Based on an average daily trading volume, of 217,400 shares, the short-interest ratio is currently 2.4 days. Currently, 1.0% of the shares of the company are short sold. View Icon's Current Options Chain.
Who are some of Icon's key competitors?
Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE) and Luna Innovations (LUNA).
What other stocks do shareholders of Icon own?
Who are Icon's key executives?
Icon's management team includes the folowing people:
- Dr. Steven A. Cutler, CEO & Director (Age 59)
- Mr. Brendan Brennan, Chief Financial Officer (Age 40)
- Jonathan Curtain, VP of Corp. Fin. & Investor Relations
- Mr. Thomas O'Leary, Chief Information Officer
- Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)
Who are Icon's major shareholders?
Icon's stock is owned by many different of retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (1.05%), Peregrine Capital Management LLC (0.43%), Envestnet Asset Management Inc. (0.36%), Summit Creek Advisors LLC (0.27%), CIBC Private Wealth Group LLC (0.23%) and Legato Capital Management LLC (0.16%).
Which major investors are selling Icon stock?
ICLR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Stephens Investment Management Group LLC, Cambiar Investors LLC, Polianta Ltd, Fulton Bank N.A., Farmers & Merchants Investments Inc., Confluence Investment Management LLC and Financial Gravity Wealth Inc..
Which major investors are buying Icon stock?
ICLR stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Arden Trust Co, Summit Creek Advisors LLC, Brinker Capital Inc., LVM Capital Management Ltd. MI, Cibc Bank USA, Envestnet Asset Management Inc. and Legato Capital Management LLC.
How do I buy shares of Icon?
Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Icon's stock price today?
One share of ICLR stock can currently be purchased for approximately $139.69.
How big of a company is Icon?
Icon has a market capitalization of $7.54 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.
What is Icon's official website?
How can I contact Icon?
Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.
MarketBeat Community Rating for Icon (NASDAQ ICLR)
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
